Your browser doesn't support javascript.
loading
Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells.
Offensperger, Fabian; Tin, Gary; Duran-Frigola, Miquel; Hahn, Elisa; Dobner, Sarah; Ende, Christopher W Am; Strohbach, Joseph W; Rukavina, Andrea; Brennsteiner, Vincenth; Ogilvie, Kevin; Marella, Nara; Kladnik, Katharina; Ciuffa, Rodolfo; Majmudar, Jaimeen D; Field, S Denise; Bensimon, Ariel; Ferrari, Luca; Ferrada, Evandro; Ng, Amanda; Zhang, Zhechun; Degliesposti, Gianluca; Boeszoermenyi, Andras; Martens, Sascha; Stanton, Robert; Müller, André C; Hannich, J Thomas; Hepworth, David; Superti-Furga, Giulio; Kubicek, Stefan; Schenone, Monica; Winter, Georg E.
Afiliação
  • Offensperger F; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Tin G; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Duran-Frigola M; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Hahn E; Ersilia Open Source Initiative, Cambridge CB1 3DE, UK.
  • Dobner S; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Ende CWA; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Strohbach JW; Medicine Design, Pfizer Worldwide Research and Development, Groton, CT 06340, USA.
  • Rukavina A; Medicine Design, Pfizer, Cambridge, MA 02139, USA.
  • Brennsteiner V; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Ogilvie K; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Marella N; Medicine Design, Pfizer Worldwide Research and Development, Groton, CT 06340, USA.
  • Kladnik K; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Ciuffa R; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Majmudar JD; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Field SD; Medicine Design, Pfizer, Cambridge, MA 02139, USA.
  • Bensimon A; Medicine Design, Pfizer, Cambridge, MA 02139, USA.
  • Ferrari L; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Ferrada E; Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna Biocenter 5, 1030 Vienna, Austria.
  • Ng A; University of Vienna, Max Perutz Labs, Vienna Biocenter 5, 1030 Vienna, Austria.
  • Zhang Z; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Degliesposti G; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Boeszoermenyi A; Molecular Informatics, Machine Learning and Computational Sciences, Early Clinical Development, Pfizer, Cambridge, MA 02139, USA.
  • Martens S; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Stanton R; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Müller AC; Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna Biocenter 5, 1030 Vienna, Austria.
  • Hannich JT; University of Vienna, Max Perutz Labs, Vienna Biocenter 5, 1030 Vienna, Austria.
  • Hepworth D; Molecular Informatics, Machine Learning and Computational Sciences, Early Clinical Development, Pfizer, Cambridge, MA 02139, USA.
  • Superti-Furga G; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Kubicek S; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
  • Schenone M; Medicine Design, Pfizer, Cambridge, MA 02139, USA.
  • Winter GE; CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
Science ; 384(6694): eadk5864, 2024 Apr 26.
Article em En | MEDLINE | ID: mdl-38662832
ABSTRACT
Chemical modulation of proteins enables a mechanistic understanding of biology and represents the foundation of most therapeutics. However, despite decades of research, 80% of the human proteome lacks functional ligands. Chemical proteomics has advanced fragment-based ligand discovery toward cellular systems, but throughput limitations have stymied the scalable identification of fragment-protein interactions. We report proteome-wide maps of protein-binding propensity for 407 structurally diverse small-molecule fragments. We verified that identified interactions can be advanced to active chemical probes of E3 ubiquitin ligases, transporters, and kinases. Integrating machine learning binary classifiers further enabled interpretable predictions of fragment behavior in cells. The resulting resource of fragment-protein interactions and predictive models will help to elucidate principles of molecular recognition and expedite ligand discovery efforts for hitherto undrugged proteins.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteômica / Bibliotecas de Moléculas Pequenas / Descoberta de Drogas / Aprendizado de Máquina Limite: Humans Idioma: En Revista: Sci. (N.Y., N.Y.) / Science Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteômica / Bibliotecas de Moléculas Pequenas / Descoberta de Drogas / Aprendizado de Máquina Limite: Humans Idioma: En Revista: Sci. (N.Y., N.Y.) / Science Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Áustria